A study questioned how long patients needed to return to full baseline functionality (FBF) after repeated intermittent use of midazolam nasal spray (MDZ-NS) to treat seizure clusters (SCs). “The vast majority of patients returned to FBF within 24 [hours] of intermittent administration of one or two MDZ-NS doses, with a similar median time to return to FBF. These return to FBF data further support the favorable profile of repeated intermittent MDZ-NS use in patients with SCs,” the study authors wrote in their conclusion.

Read more.